FindTrial
Sign In

Use of the beta-tricalcium phospate on maxillar sinus floor augumentation

Use of the beta-tricalcium phospate on maxillar sinus floor augumentation-a randomized clinical controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-7qhkrn
Enrollment
Unknown
Registered
2016-11-11
Start date
2015-02-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alveolar bone loss

Interventions

Test Group- A sinus floor augumentation procedure will be perform and the maxxilary sinus will be fill with Beta-TCP. After 10 months, the dental implantes will be place and theses implants will be cl
Other
E04.545.668

Sponsors

Faculdade de Odontologia de Araraquara-Unesp
Lead Sponsor
Faculdade de Odontologia de Araraquara-Unesp
Collaborator

Eligibility

Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Age between 18-60 years old; presence of the necessity of the sinus floor elevation bilaterally in order to perform the dental implants placement; presence of 5mm or less of alveolar ridge bone; good systemic healthy; absence of non-healed alveolar pos-extraction sites

Exclusion criteria

Exclusion criteria: Smokers or ex-smokers; diabetics; presence of chronic or agressive periodontitis; users of medications which alter the bone metabolism; presence of cronic respiratory infections; Chronic users of antiinflamatory or antibiotics; bruxism; chronic alcohol users; drug users; pregnants; history of radiotherapy at the head and neck region; presence of bone pathologies or disease which affect the bone mtabolism

Design outcomes

Primary

MeasureTime frame
To evaluated the differences regarding the bone disponibility and clinical outcomes of the implantes placed in grafted areas with the association of beta-TCP with autogenous bone or with the use of beta-TCP after maxillary sinus lifting procedures with will be evaluated by the tomographic analysis and clinical, radiographic, and stability of the implants.—

Secondary

MeasureTime frame
To evaluate the biological mechanisms by which the combination of beta-TCP with autogenous bone and the Isolated use of beta-TCP can promote formation of bone tissue. This outcome will be assessed by combining the data to be generated by histomorphometric, immunohistochemical and molecular analyzes (qPCR and Elisa)—

Countries

Brazil

Contacts

Public ContactElcio Marcantonio Junior

Faculdade de Odontologia de Araraquara-Unesp

elciojr@foar.unesp.br+55(16)33016378

Outcome results

None listed

Source: REBEC (via WHO ICTRP)